Cerevel Therapeutics Holdings, Inc. Stock
Equities
CERE
US15678U1280
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.47 USD | +0.95% | +0.62% | +0.17% |
04-18 | Sector Update: Health Care Stocks Mixed Pre-Bell Thursday | MT |
04-18 | Cerevel Therapeutics' Potential Parkinson's Treatment Meets Primary Endpoint in Phase 3 Study | MT |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 7.71B 10.54B |
---|---|---|---|---|---|
Net income 2024 * | -456M -623M | Net income 2025 * | -551M -753M | EV / Sales 2024 * | - |
Net cash position 2024 * | 619M 846M | Net cash position 2025 * | 690M 943M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-17
x | P/E ratio 2025 * |
-15.1
x | Employees | 334 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 42.24% |
Latest transcript on Cerevel Therapeutics Holdings, Inc.
1 day | +0.95% | ||
1 week | +0.62% | ||
Current month | +0.47% | ||
1 month | +0.21% | ||
3 months | +0.95% | ||
6 months | +85.86% | ||
Current year | +0.17% |
Managers | Title | Age | Since |
---|---|---|---|
Ronald Renaud
CEO | Chief Executive Officer | 55 | 23-06-11 |
Director of Finance/CFO | 43 | 23-05-14 | |
N. Coles
CHM | Chairman | 63 | 18-11-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 63 | 19-05-31 | |
Douglas Giordano
BRD | Director/Board Member | 61 | 18-08-31 |
Ruth McKernan
BRD | Director/Board Member | 66 | 20-12-03 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.10% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 42.47 | +0.95% | 680,906 |
24-04-25 | 42.07 | +0.41% | 691,659 |
24-04-24 | 41.9 | -0.21% | 629,646 |
24-04-23 | 41.99 | -0.26% | 1,390,239 |
24-04-22 | 42.1 | -0.26% | 701,473 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.17% | 7.71B | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- CERE Stock